-+ 0.00%
-+ 0.00%
-+ 0.00%

OSE Immunotherapeutics says Combi-TED Phase 2 topline Tedopi results in metastatic NSCLC win oral slot at ESMO 2026

PUBT·09/23/2026 05:30:28
Listen to the news
OSE Immunotherapeutics says Combi-TED Phase 2 topline Tedopi results in metastatic NSCLC win oral slot at ESMO 2026
  • OSE Immunotherapeutics announced Combi-TED Phase 2 topline results for Tedopi in metastatic non-small cell lung cancer.
  • Data will be presented at the ESMO 2026 meeting in Madrid on Oct. 25, 2026; results have not yet been presented.
  • The study tested Tedopi combinations as second-line treatment versus a docetaxel-only reference arm in 105 eligible patients.
  • Topline readout supports continued evaluation of Tedopi in this setting, with overall survival at one year as the primary outcome.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OSE Immunotherapeutics SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609230130PRIMZONEFULLFEED1001274093) on September 23, 2026, and is solely responsible for the information contained therein.